Athena Diagnostics, Inc. provides clinical diagnostics testing laboratory services. The firm focuses on neurology, endocrinology, hearing loss and nephrology. It offers tests for Alzheimer's disease, muscular dystrophy and other neuromuscular and developmental disorders. The company was founded in 1988 and is headquartered in Marlborough, MA.

Cancer Research Ventures Ltd. engages in the business of research and experimental development on biotechnology. It provides medical products. The company is headquartered in London, the United Kingdom.

Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

Consiglio Nazionale delle Ricerche is the largest public research facility in Italy. Founded in 1923, it has worked in the past as a government consultant on research and as a funding fund for university research grants. Since 1989 the CNR is a research institution, with the mission of carrying out research projects, promoting innovation and competitiveness of the national industrial system, the internationalization of the national research system, and providing technologies and solutions to emerging needs in the public and private sectors. . Objectives that are achieved through a wealth of human resources that has over 8000 employees, half of which is represented by researchers and technologists. About 4,000 young researchers are involved in post-doctoral research activities in the laboratories of the Institute, while an important contribution comes from collaborations, including international ones, with researchers from universities and companies, thus strengthening the national research system.

Otsuka Holdings operates in pharmaceuticals, nutraceuticals, and consumer products. The business activity of the company includes providing healthcare solutions in the areas of the nervous system, oncology, cardiovascular system, respiratory system, infectious disease, and others. The company engages in the research and development of functional foods and beverages, such as electrolyte drinks, nutritional foods, soy snacks, and dietary foods.

At the beginning of the twentieth century, tuberculosis was one of the UK’s most urgent health problems. A royal commission, entitled The Royal Commission Appointed to Inquire into the Relations of Human and Animal Tuberculosis, was set up in 1901. It aimed to find out whether tuberculosis in animals and humans was the same disease and whether animals and humans could infect each other. This page describes how, by 1919, the Commission had evolved into the independent Medical Research Council.

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

Wuhan Liangpei Medical Laboratory Co., Ltd., established on 2015-08-12, Business scope includes third-party medical testing,molecular diagnosis,Gene Sequencing Research;Drug Discovery;In vitro diagnostic reagent development.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Genetics Generation Advancement Corp. engages in the provision of genetic testing, molecular diagnostics, biotechnology services, personal health-related testing services, biological information services, and health care services. It offers testing, pre-implantation stage, prenatal stage, newborn medical examination, adult healthcare health management genetic testing, adult healthcare cancer pharmacogenetics testing and other related testing services. The company was founded on November 21, 2008 and is headquartered in Taipei, Taiwan.

DKFZ Deutsche Krebsforschungszentrum is a German private company that operates as a cancer research center.

Beijing Shenggu Tongchuang Technology Development Co., Ltd., established on 2012-02-28, Business scope includes technology development,technology transfer,technical consulting,Technical Services;Medical Research and Experimental Development;Sales of chemical products(Does not contain dangerous chemicals and a class of precursor chemicals);Import and export,Agent import and export,Technology Import and Export;Sales of medical devicesI,II,IIIkind.(Enterprises independently choose operating projects according to law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)

In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. At Takeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer. They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.

Weihansi Shengwu is engaged in genetic disease screening and diagnosis, abortion product detection, single gene blockade of new mutations, and a technical service platform for gene detection of genetic diseases and the prevention and control of birth defects.

Beijing Shenggu Zhihui Medical Laboratory Co., Ltd., established on 2015-09-02, The scope of business includes medical laboratory,Pathology Medical Services;Sales of chemical products(Free of Hazardous Chemicals),Instrumentation,Equipment,Class I medical device;technology development,Technical Services,technical consulting(Except intermediary),technology transfer;Technical testing;Import and export(Excluding state trade management goods),Technology Import and Export,Agent import and export;market survey;Marketing Planning;Investment Advisory(Except intermediary);investment management;computer system integration;selling computers,Software and Auxiliary Equipment;Economic Information Consulting.(Market entities independently choose business projects in accordance with the law,Carry out business activities;Medical Laboratory,Pathology medical services and items subject to approval according to law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. The company also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.